Valproic acid and nonalcoholic fatty liver disease: A possible association?
Open Access
- 1 January 2015
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 7 (9) , 1251-7
Abstract
Valproic acid (VPA) is one of the most prescribed drugs in children with newly diagnosed epilepsy. Weight gain and obesity have been observed as side effects of VPA. These are often linked with other metabolic disturbances such as development of insulin resistance, dyslipidemia, metabolic syndrome (MetS) and non-alcoholic fatty liver disease or nonalcoholic fatty liver disease (NAFLD). NAFLD refers to a group of liver disorders with marked hepatic steatosis. It is associated with an increased incidence of cardiovascular diseases and overall reduced life expectancy. NAFLD occurs in 20%-25% of the general population and it is known to be the most common cause of chronic liver disease. NAFLD therefore represents a major public health issue worldwide. This study reviews and summarizes relevant literature that supports the existence of an association between VPA therapy and the development of NAFLD in children. Long-term VPA-therapy appears to be associated with an increased risk of developing NAFLD. Further studies are needed to clarify the pathogenic mechanisms that lie behind this association and to standardize the options for the use of this drug in overweight patients and in those with risks for developing MetS and NAFLD.Keywords
This publication has 50 references indexed in Scilit:
- A 360-degree overview of paediatric NAFLD: Recent insightsJournal of Hepatology, 2013
- Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targetsBMC Pediatrics, 2013
- Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implicationsObesity Reviews, 2011
- The metabolic syndrome in overweight epileptic patients treated with valproic acidEpilepsia, 2010
- Nonalcoholic Fatty Liver Disease as a Comorbidity of Childhood ObesityPediatric Health, 2009
- Nonalcoholic fatty liver disease during valproate therapyEuropean Journal of Pediatrics, 2009
- Sodium valproate inhibits glucose transport and exacerbates Glut1‐deficiency in vitroJournal of Cellular Biochemistry, 2005
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Valproate–Induced Hepatic Steatogenesis in RatsHepatology, 1982
- Effects of sodium valproate in 100 children with special reference to weight.BMJ, 1981